UK hypermobility sufferers wait up to 21 years for diagnosis, study suggests - The Guardian

Summary

People in the UK with hypermobility conditions are waiting up to 21 years to be diagnosed while suffering from symptoms ranging from chronic pain to partially dislocated joints, research suggests.

The study of more than 2,000 people, which was led by the University of Edinburgh and described as the…

Source: The Guardian

(0)

AI News Q&A (Free Content)

This content is freely available. No login required. Disclaimer: Following content is AI generated from various sources including those identified below. Always check for accuracy. No content here is an advice. Please use the contact button to share feedback about any inaccurate content generated by AI. We sincerely appreciate your help in this regard.

Q1: What is the average diagnostic delay for individuals with hypermobility conditions in the UK, and what are some of the symptoms they experience?

A1: The average diagnostic delay for individuals with hypermobility conditions such as hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSD) in the UK is between 19 to 21.7 years. Common symptoms include chronic pain experienced by 84% of patients, partially dislocated joints in 74%, and gastrointestinal issues in 66% of the surveyed individuals.

Q2: How do hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSD) affect an individual's life beyond physical symptoms?

A2: hEDS and HSD significantly impact various aspects of life, including education, employment, and mental health. The study found that 47.9% of individuals were dependent on benefits, 55.9% had disrupted education, and 45.6% were unemployed. Additionally, high rates of neurodivergence were noted, with 20% reporting autism spectrum disorder, 18% ADHD, and 15% dyslexia.

Q3: What are the current challenges in diagnosing and managing hypermobility disorders in the UK?

A3: Challenges in diagnosing and managing hypermobility disorders include prolonged diagnostic delays, reliance on private healthcare, and fragmented care pathways. There is a significant need for coordinated, multidisciplinary care approaches to address the complex and multisystemic nature of these disorders.

Q4: What recent developments have been made in understanding the pathophysiology of hEDS and HSD?

A4: Recent studies emphasize the recognition of hEDS and HSD as complex, multisystem connective tissue disorders. Emerging evidence suggests that these conditions involve chronic pain, autonomic dysfunction, immune dysregulation, and structural fragility. However, the specific genetic markers for hEDS remain unidentified.

Q5: How does hypermobility spectrum disorder relate to other neurodevelopmental disorders?

A5: There is a strong association between hypermobility spectrum disorder and neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). This link highlights the need for a broader understanding of HSD as a condition that affects multiple systems beyond musculoskeletal symptoms.

Q6: What steps are being recommended to improve the healthcare experience for individuals with hypermobility disorders in the UK?

A6: Experts recommend the development of equitable, multidisciplinary care pathways that are co-designed with patients. These pathways should focus on reducing diagnostic delays, improving care coordination, and addressing the wide-ranging impacts of hEDS and HSD on patients' lives.

Q7: What are the implications of the University of Edinburgh's study on future healthcare policies for hypermobility conditions?

A7: The University of Edinburgh's study underscores the urgent need for policy changes to provide earlier recognition and better access to knowledgeable professionals for individuals with hEDS and HSD. The study's findings advocate for improved awareness and understanding of these conditions among healthcare professionals, policymakers, and the public.